Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
Stock Summary
Top Correlated Resources
006280.KS
Top 10 Correlated ETFs
006280.KS
Top 10 Correlated Stocks
006280.KS
Financial details
Company Rating
Strong Buy
Market Cap
1637.79B
Income
124.74B
Revenue
1708.17B
Book val./share
111493.35
Cash/share
17983.32
Dividend
2000
Dividend %
1.56%
Employees
2.07K
Optionable
No
Shortable
Yes
Earnings
31 Oct 2022
P/E
11.76
Forward P/E
-
PEG
14.25
P/S
0.86
P/B
1.15
P/C
7.15
P/FCF
86.56
Quick Ratio
0.36
Current Ratio
1.95
Debt / Equity
0.3
LT Debt / Equity
0.25
-
-
EPS (TTM)
7.69K
EPS next Y
-
EPS next Q
-
EPS this Y
-83.46%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-24.11%
Revenue last 5Y
3.61%
Revenue Q/Q
1.51%
EPS Q/Q
457.15%
-
-
-
-
SMA20
-13.96%
SMA50
-18.26%
SMA100
-23.48%
Inst Own
0%
Inst Trans
0%
ROA
5%
ROE
10%
ROC
0.06%
Gross Margin
35%
Oper. Margin
7%
Profit Margin
7%
Payout
18%
Shs Outstand
11.41M
Shs Float
5.45M
-
-
-
-
Target Price
-
52W Range
143000.0-360500.0
52W High
-64.36%
52W Low
-10.14%
RSI
19.18
Rel Volume
2.36
Avg Volume
29.86K
Volume
70.59K
Perf Week
-16.29%
Perf Month
-26.78%
Perf Quarter
-36.39%
Perf Half Y
-36.54%
-
-
-
-
Beta
1.25085
-
-
Volatility
6304.36%, 11413.25%
Prev Close
-4.1%
Price
128500
Change
-6.55%
Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 112.84K | 116.96K | 120.01K | 131.79K | 14.66K | |
| Net income per share | 4.67K | 3.02K | -318.72 | 7.1K | 1.17K | |
| Operating cash flow per share | 5.07K | 1.26K | 3.53K | 3.15K | 1.2K | |
| Free cash flow per share | 202.32 | -4.44K | -9.4K | -5.73K | 23.26 | |
| Cash per share | 15K | 9.35K | 12.4K | 22.39K | 1.93K | |
| Book value per share | 91.14K | 92.84K | 91.89K | 98K | 12.15K | |
| Tangible book value per share | 89.44K | 89.84K | 94.72K | 101.61K | 11.65K | |
| Share holders equity per share | 91.14K | 92.84K | 91.89K | 98K | 12.15K | |
| Interest debt per share | 27.98K | 29.47K | 43.18K | 50.54K | 5.9K | |
| Market cap | 2824.76B | 1506.54B | 1472.3B | 4833.48B | 18409.77B | |
| Enterprise value | 2966.77B | 1738.68B | 1857.02B | 5167.62B | 18830.29B | |
| P/E ratio | 53.05 | 43.76 | -404.75 | 59.64 | 149.42 | |
| Price to sales ratio | 2.19 | 1.13 | 1.07 | 3.21 | 11.97 | |
| POCF ratio | 48.8 | 104.55 | 36.54 | 134.36 | 146.13 | |
| PFCF ratio | 1.22K | -29.76 | -13.72 | -73.88 | 7.54K | |
| P/B Ratio | 2.72 | 1.42 | 1.4 | 4.32 | 14.44 | |
| PTB ratio | 2.72 | 1.42 | 1.4 | 4.32 | 14.44 | |
| EV to sales | 2.3 | 1.3 | 1.36 | 3.44 | 12.24 | |
| Enterprise value over EBITDA | 26.56 | 17.73 | 32.14 | 33.22 | 82.87 | |
| EV to operating cash flow | 51.26 | 120.66 | 46.09 | 143.65 | 149.47 | |
| EV to free cash flow | 1.28K | -34.34 | -17.3 | -78.99 | 7.72K | |
| Earnings yield | 0.02 | 0.02 | 0 | 0.02 | 0.01 | |
| Free cash flow yield | 0 | -0.03 | -0.07 | -0.01 | 0 | |
| Debt to equity | 0.3 | 0.25 | 0.33 | 0.24 | 0.29 | |
| Debt to assets | 0.35 | 0.35 | 0.4 | 0.41 | 0.39 | |
| Net debt to EBITDA | 1.27 | 2.37 | 6.66 | 2.15 | 1.85 | |
| Current ratio | 3.56 | 2.94 | 2.4 | 1.92 | 1.98 | |
| Interest coverage | 14.32 | 6.6 | 4.19 | 4.86 | 5.9 | |
| Income quality | 1.09 | 0.42 | -11.08 | 0.44 | 1.02 | |
| Dividend Yield | 0.01 | 0.01 | 0.01 | 0 | 0 | |
| Payout ratio | 0.29 | 0.45 | -3.4 | 0.16 | 0.15 | |
| Sales general and administrative to revenue | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Research and developement to revenue | 0.08 | 0.09 | 0.09 | 0.09 | 0.09 | |
| Intangibles to total assets | 0.05 | 0.06 | 0.05 | 0.05 | 0.11 | |
| Capex to operating cash flow | -0.96 | -4.51 | -3.66 | -2.82 | -0.98 | |
| Capex to revenue | -0.04 | -0.05 | -0.11 | -0.07 | -0.08 | |
| Capex to depreciation | -1.51 | -1.62 | -3.16 | -2.08 | -2.21 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 97.81K | 79.38K | 25.67K | 125.14K | 17.92K | |
| ROIC | 0.06 | 0.04 | 0.03 | 0.03 | 0.04 | |
| Return on tangible assets | 0.03 | 0.02 | 0 | 0.04 | 0.06 | |
| Graham Net | -20.41K | -26.02K | -37.71K | -35.75K | -5.07K | |
| Working capital | 666.48B | 589.95B | 560.36B | 542.64B | 542.74B | |
| Tangible asset value | 1020.8B | 1025.37B | 1081.06B | 1159.74B | 1222.35B | |
| Net current asset value | 331.67B | 296.23B | 186.56B | 249.95B | 133.23B | |
| Invested capital | 0.3 | 0.31 | 0.46 | 0.51 | 0.48 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 146.79B | 139.86B | 137.03B | 134.78B | 127.16B | |
| Average inventory | 409.17B | 412B | 421.81B | 437.07B | 446.02B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 62.93 | 53.49 | 50.97 | 46.26 | 42.89 | |
| Days of inventory on hand | 151.08 | 142.8 | 148.78 | 150.01 | 163.25 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 5.8 | 6.82 | 7.16 | 7.89 | 8.51 | |
| Inventory turnover | 2.42 | 2.56 | 2.45 | 2.43 | 2.24 | |
| ROE | 0.05 | 0.03 | 0 | 0.07 | 0.1 | |
| Capex per share | -4.87K | -5.7K | -12.93K | -8.88K | -1.18K |
Quarterly Fundamentals Overview
Last date of statement is 2022-06-30 for Q2
| Metric | History | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 33.96K | 40.8K | 12.8K | 13.27K | 37.06K | |
| Net income per share | 266.36 | 4.71K | 1.65K | 203.35 | 1.13K | |
| Operating cash flow per share | 3.46K | 596.43 | 2.92K | 503.75 | 497.85 | |
| Free cash flow per share | 1.31K | -1.31K | 1.49K | -69.1 | -1.11K | |
| Cash per share | 20.45K | 17.2K | 6.46K | 0 | 17.98K | |
| Book value per share | 98.18K | 103.29K | 40.57K | 40.02K | 111.49K | |
| Tangible book value per share | 102.07K | 107.42K | 38.9K | 47.92K | 108.05K | |
| Share holders equity per share | 98.18K | 103.29K | 40.57K | 40.02K | 111.49K | |
| Interest debt per share | 57.58K | 54.8K | 19.4K | -254.84 | 57.88K | |
| Market cap | 3749.23B | 3783.66B | 6849.78B | 6347.04B | 1924.06B | |
| Enterprise value | 4190.89B | 4229.92B | 7270.29B | 6347.04B | 2404.45B | |
| P/E ratio | 308.32 | 17.61 | 33.12 | 248.33 | 37.18 | |
| Price to sales ratio | 9.67 | 8.12 | 17.03 | 15.22 | 4.55 | |
| POCF ratio | 94.98 | 555.8 | 74.56 | 400.99 | 338.45 | |
| PFCF ratio | 251.15 | -253.84 | 146.64 | -2.92K | -151.72 | |
| P/B Ratio | 3.35 | 3.21 | 5.37 | 5.05 | 1.51 | |
| PTB ratio | 3.35 | 3.21 | 5.37 | 5.05 | 1.51 | |
| EV to sales | 10.81 | 9.08 | 18.07 | 15.22 | 5.68 | |
| Enterprise value over EBITDA | 186.18 | 46.1 | 94.76 | 223.76 | 69.54 | |
| EV to operating cash flow | 106.17 | 621.36 | 79.14 | 400.99 | 422.96 | |
| EV to free cash flow | 280.74 | -283.78 | 155.64 | -2.92K | -189.6 | |
| Earnings yield | 0 | 0.01 | 0.01 | 0 | 0.01 | |
| Free cash flow yield | 0 | 0 | 0.01 | 0 | -0.01 | |
| Debt to equity | 0.31 | 0.29 | 0.29 | 0 | 0.3 | |
| Debt to assets | 0.43 | 0.42 | 0.39 | 0.4 | 0.39 | |
| Net debt to EBITDA | 19.62 | 4.86 | 5.48 | 0 | 13.89 | |
| Current ratio | 1.94 | 2.07 | 1.98 | 1.95 | 1.95 | |
| Interest coverage | 3.58 | 21.36 | -4.6 | -5.23 | 2.98 | |
| Income quality | 12.98 | 0.13 | 1.78 | 2.48 | 0.44 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0.01 | |
| Payout ratio | 6.07 | 0 | 0 | 0.01 | 1.85 | |
| Sales general and administrative to revenue | 0.03 | 0.02 | 0.03 | 0.25 | 0.02 | |
| Research and developement to revenue | 0.07 | 0.09 | 0.12 | 0 | 0.12 | |
| Intangibles to total assets | 0.05 | 0.05 | 0.11 | 0 | 0.11 | |
| Capex to operating cash flow | -0.62 | -3.19 | -0.49 | -1.14 | -3.23 | |
| Capex to revenue | -0.06 | -0.05 | -0.11 | -0.04 | -0.04 | |
| Capex to depreciation | -1.89 | -1.65 | -2.73 | -1.15 | -1.16 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 24.26K | 104.57K | 38.76K | 13.53K | 53.31K | |
| ROIC | 0.01 | 0.04 | -0.01 | 0.02 | 0.01 | |
| Return on tangible assets | 0 | 0.02 | 0.02 | 0 | 0.01 | |
| Graham Net | -43.59K | -47.15K | -16.93K | -31.85K | -49.55K | |
| Working capital | 541.95B | 601.62B | 542.74B | 554.4B | 538.87B | |
| Tangible asset value | 1164.98B | 1226.08B | 1222.35B | 0 | 1233.76B | |
| Net current asset value | 146.47B | 201.76B | 133.23B | 135.81B | 114.92B | |
| Invested capital | 0.58 | 0.53 | 0.48 | 0 | 0.52 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 35.58 | 35.95 | 38.91 | 0 | 35.61 | |
| Days of inventory on hand | 158.87 | 147.38 | 148.11 | 0 | 140.64 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 2.53 | 2.5 | 2.31 | 0 | 2.53 | |
| Inventory turnover | 0.57 | 0.61 | 0.61 | 0 | 0.64 | |
| ROE | 0 | 0.05 | 0.04 | 0.01 | 0.01 | |
| Capex per share | -2.15K | -1.9K | -1.44K | -572.86 | -1.61K |
Frequently Asked Questions
What is Green Cross Corporation stock symbol ?
Green Cross Corporation is a US stock and trading under the symbol 006280.KS
What is Green Cross Corporation stock quote today ?
Green Cross Corporation stock price is $128500 today.
Is Green Cross Corporation stock public?
Yes, Green Cross Corporation is a publicly traded company.
Company Profile
- Volume Average 29.86K
- Market Capitalization 1637.79B
- Employee 2.07K
- Headquarters Yongin-Si,US
- IPO Date 2000-01-04
-
Website
https://www.globalgreencross.com 
Green Cross Corporation, a biopharmaceutical company, develops drugs and vaccines in South Korea. The company provides plasma derivatives, including albumin, immunoglobulin, and antithrombin; and vaccines for hepatitis-B, Hantavirus hemorrhagic fever, influenza, flu, and varicella. It also offers prescription drugs for the bleeding symptom control and hemostasis for persons with hemophilia A; prevention and treatment of bleeding episodes induced by hemophilia A and post-operative treatment; and treatment of neutropenia, hunter syndrome, and liver cancer, as well as treatment of anti-inflammation, pain relief, and osteoarthritis. In addition, the company provides over the counter drugs. It also exports its products to approximately 50 countries. The company has a licensing and collaboration agreement with Tottori University for development of GM1 gangliosidosis chaperone therapy. The company was formerly known as Sudo Microorganism Medical Supplies Company and changed its name to Green Cross Corporation in 1971. Green Cross Corporation was founded in 1967 and is headquartered in Yongin-si, South Korea. Green Cross Corporation is a subsidiary of Green Cross Holdings Corporation.
